Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The clinical implications of RSK1-3 in human breast cancer

Zhao, Huishan, Martin, Tracey Amanda ORCID: https://orcid.org/0000-0003-2690-4908, Davies, Eleri-Lloyd, Ruge, Fiona, Yu, Hefen, Zhang, Y., Teng, Xu and Jiang, Wen Guo ORCID: https://orcid.org/0000-0002-3283-1111 2016. The clinical implications of RSK1-3 in human breast cancer. Anticancer Research 36 (3) , pp. 1267-1274.

Full text not available from this repository.

Abstract

ackground/Aim: The ribosomal S6 protein kinase (RSK) family is an important effector of extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) that could influence tumour metastasis by phosphorylating proteins in both the nuclear and cytoplasmic compartments. Aberrant expression of RSK is evident in certain malignancies but the role played by RSK in breast cancer is still not clear. This study aimed to examine the expression of RSK in human breast cancer specimens and its role to breast cancer metastasis. Materials and Methods: The expression of RSK1 to -3 were separately examined in human breast cancer tissues (normal, n=33; cancer, n=112) using quantitative real-time polymerase chain reaction (Q-PCR) and immunohistochemistry. Migration and adhesion of breast cancer cells treated with the RSK inhibitor SL0101 were investigated by electric cell impedance sensing (ECIS). The effect on growth and invasion of RSK1-3 was then investigated using in vitro models. Results: The clinical data and immunohistochemistry revealed that expression of RSK1 and RSK3 were less in tumour tissues than normal. mRNA expression of RSK2 was negatively correlated with grade, TNM staging, and survival rate. SL0101 inhibited adhesion of the MCF-7 and MDA-231 breast cancer cell lines. SL0101 suppressed MDA-231 invasion and the alternate RSK inhibitor BRD7389 inhibited the invasion of MCF-7 and MDA-231 cells. Conclusion: RSK1 and 3 but not RSK2 are down-regulated in breast tumour and are associated with disease progression. RSK may be a key component in the progression and metastasis of breast cancer.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher: International Institute of Anticancer Research
ISSN: 1791-7530
Funders: Cardiff China Medical Scholarship and Cancer Research Wales
Date of First Compliant Deposit: 11 April 2016
Date of Acceptance: 14 February 2016
Last Modified: 01 Nov 2022 09:44
URI: https://orca.cardiff.ac.uk/id/eprint/89064

Citation Data

Cited 9 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item